The BASE Study: Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)

Completed · Phase 3 · Has a placebo group

Conditions studied: Chronic Kidney Disease

In brief

The two doses of sodium bicarbonate being tested are 0.5 and 0.8 mEq/kg-lean body weight (LBW) per day. Sodium bicarbonate, also known as baking soda, may help prevent kidney failure in people with chronic kidney disease. However, the dose to prescribe in order to test this possibility in a clinical trial is uncertain. The BASE pilot clinical trial will help determine the best dose of sodium bicarbonate to prescribe in a future study that will test the long-term safety and efficacy of sodium bicarbonate as a treatment to preserve kidney function in individuals with chronic kidney disease.

Key facts

Study ID

NCT02521181

Run by

Jennifer Gassman, PhD

People needed

194

Starts

2015-10-01

Expected to finish

2018-06-01

Last updated by the study team

2020-10-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Serum bicarbonate 20-28 mEq/L at screening (the average of the two most recent values in Baseline must be 20-28 mEq/L prior to randomization)
• Moderate to severe chronic kidney disease (CKD) at the time of screening, defined as one of the following:
• eGFR 20-44 ml/min/1.73m2 or
• eGFR 45-59 ml/min/1.73m2 plus random urinary albumin:creatinine (ACR) ≥100 mg/gm
• Blood pressure <160/100 mm Hg at screening (must be <150/100 mm Hg prior to randomization)
• Lean body weight 38.0-96.0 kg at the time of screening
• Age allowing legal consent without parental involvement (18-21 years, depending on individual state regulations)
• Able to provide consent
• Able to travel to study visits
• Able to read English
• In the opinion of the site investigator, willing and able to follow the study treatment regimen and comply with the site investigator's recommendations
• In the opinion of the site investigator, medically stable

You may not qualify if…

• Use of chronic daily oral alkali (such as sodium bicarbonate, sodium citrate, potassium citrate, etc) with one exception: calcium carbonate ≤1500 mg/day is allowed, as some will take this for the indication of bone health
• On five or more antihypertensive and/or diuretic agents, regardless of the indication
• Serum potassium <3.3 or ≥5.5 mEq/L at screening (must be 3.5-5.5 mEq/L prior to randomization)
• Self-reported vegetarian
• New York Heart Association Class 3 or 4 heart failure symptoms, known left ventricular ejection fraction ≤30%, or hospital admission for heart failure within the past 3 months
• Frequent urinary tract infections (≥2 in the past year)
• Presence of indwelling urinary catheter or urinary conduit (such as neobladder or urostomy)
• Factors judged to limit adherence to interventions (e.g., alcoholism, history of missing clinic visits, chronic gastrointestinal disorder that makes compliance with the intervention unreliable)
• Organ transplant recipients (excluding cornea)
• Active glomerular disease requiring or potentially requiring immunosuppressive treatment
• Chronic immunosuppressive therapy (for ≥3 months) for any indication. This does not include oral steroids <10 mg per day, inhaled steroids, or topical steroids
• Anticipated initiation of dialysis or kidney transplantation within 12 months as assessed by the site investigator
• Current participation in another interventional research study
• Malignancy requiring therapy within 2 years (basal or squamous cell skin carcinoma and localized prostate cancer are exempted)
• Pregnancy or planning to become pregnant or currently breast-feeding. Women of childbearing potential (pre-menopausal and not surgically sterilized) will have urine pregnancy test before enrollment.
• Life expectancy <12 months as determined by the site investigator
• Institutionalized individuals, including prisoners and nursing home residents
• Plans to leave the immediate area within the next 12 months
• Routinely leaves town for multiple weeks each year such that protocol visits would be missed
• Chronic use of supplemental oxygen
• Use of both angiotensin-converting-enzyme inhibitor (ACEI) and Angiotensin II Receptor Blockers (ARBs)

Where it is running

• Denver Nephrology Research — Denver, Colorado, United States
• George Washington University — Washington D.C., District of Columbia, United States
• Northwestern University — Chicago, Illinois, United States
• Data Coordinating Center; Cleveland Clinic Foundation; Quantitative Health Sciences; 9500 Euclid Avenue — Cleveland, Ohio, United States
• Baylor/Scott & White — Temple, Texas, United States
• University of Utah — Salt Lake City, Utah, United States
• Utah VA — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.